Simplify Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Simplify Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$559K	Buy	3,315 +810	+32%	+$120K	0.01%	105
2026 Q1	$330K	Sell	2,505 -899	-26%	-$119K	0.01%	115
2025 Q4	$483K	Sell	3,404 -33,220	-91%	-$4.81M	0.01%	101
2025 Q3	$5.14M	Sell	36,624 -9,873	-21%	-$1.34M	0.09%	33
2025 Q2	$5.84M	Buy	46,497 +26,223	+129%	+$3.01M	0.29%	22
2025 Q1	$2.24M	Buy	+20,274	New	+$2.57M	0.08%	43
2024 Q3	–	Sell	-22,834	Closed	-$3.14M	–	121
2024 Q2	$3.14M	Buy	+22,834	New	+$3.13M	0.21%	38

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12B AUM

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Simplify Asset Management's NBIX Position: Q2 2026 in Review

Simplify Asset Management increased its Neurocrine Biosciences (NBIX) stake by 32% in Q2 2026, buying an estimated $120K and bringing the position to 3,315 shares worth $559K. The position accounts for 0.01% of the portfolio, ranked #105.

Simplify Asset Management first reported a position in NBIX in Q2 2024 and has held it in 7 quarters since. The position peaked at $5.84M in Q2 2025. 92 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Simplify Asset Management held 3,315 shares of Neurocrine Biosciences worth $559K as of Q2 2026.
Simplify Asset Management bought 810 Neurocrine Biosciences shares in Q2 2026, an estimated $120K.
Neurocrine Biosciences made up 0.01% of Simplify Asset Management's portfolio in Q2 2026, its #105 holding.
Simplify Asset Management first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 7 quarters since.
Simplify Asset Management's Neurocrine Biosciences position peaked at $5.84M in Q2 2025.
92 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Simplify Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.